Breast Cancer Coverage from Every Angle

Radiotherapy-Induced Tumors and Li-Fraumeni Syndrome in Patients With Breast Cancer

By: Cordi Craig
Posted: Thursday, May 14, 2020

For patients with Li-Fraumeni syndrome, the risk of radiotherapy-induced malignancies is an important concern. Recent findings from a retrospective cohort of patients treated for localized breast cancer found the incidence of such tumors in patients with Li-Fraumeni syndrome was lower than in previous studies. Furthermore, early molecular diagnoses showed critical impacts on treatment decisions among these patients. The report was originally slated for presentation at the 2020 NCCN Annual Conference (Abstract CLO20-031) but published in the JNCCN–Journal of the National Comprehensive Cancer Network.

“Careful evaluation of risks and benefits is essential for the treatment decision-making process, especially for Li-Fraumeni patients,” Vanessa Petry Helena Bragaia, MD, of the Universidade de São Paulo, and colleagues concluded.

To analyze the effects of treating localized breast cancer in patients with Li-Fraumeni syndrome, the research team retrospectively evaluated 16 patients with pathogenic variants of TP53, associated with Li-Fraumeni syndrome, in a Brazilian cohort. All of the patients were treated for localized breast cancer between December 1999 and October 2017.

Of the 16 treated patients, 13 had invasive ductal carcinoma, and 3 had ductal carcinoma in situ. By the time of cancer treatment, three patients had known TP53 status. The incidence of radiotherapy-induced malignancies after cancer treatment was lower than the researchers anticipated based on the medical literature. More than half of the patient population (n = 12) received adjuvant radiotherapy, and just two of them developed radiotherapy-induced malignancies.

Disclosures: The authors reported no conflict of interest.

By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.